## **Core Concept**
Phosphofructokinase-1 (PFK-1) is a key regulatory enzyme in the glycolytic pathway, catalyzing the conversion of fructose-6-phosphate into fructose-1,6-bisphosphate. Inhibitors of PFK-1 can affect glycolysis, impacting energy production in cells. Understanding PFK-1 inhibitors is crucial in the context of metabolic regulation and potential therapeutic applications.

## **Why the Correct Answer is Right**
The correct answer involves understanding the specific inhibitors of PFK-1. Among the options provided, **Citrate** is known to inhibit PFK-1. Citrate acts as an allosteric inhibitor of PFK-1, signaling a surplus of biosynthetic and energy precursors. When citrate levels are high, it indicates that the cell has sufficient energy and biosynthetic building blocks, thereby reducing the need for glycolysis.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because, without specifying the compound, it's impossible to assess its relevance as a PFK-1 inhibitor. However, commonly known inhibitors or activators of glycolysis should be considered in the context of PFK-1.
- **Option B:** This option is incorrect as it does not specify a known inhibitor of PFK-1. Typically, substances like ATP, citrate, and protons are known to inhibit PFK-1.
- **Option C:** This option is incorrect because, similar to Option A, without a specific compound, its role cannot be evaluated. However, certain compounds can activate or inhibit PFK-1; for instance, AMP activates PFK-1.
- **Option D:** This option is incorrect as it is marked as the correct answer but does not provide a valid reason or substance known to inhibit PFK-1.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **citrate** can serve as an inhibitor of PFK-1. This is crucial in understanding metabolic regulation, especially in conditions like diabetes or cancer, where glycolysis is altered.

## **Correct Answer:** C. Citrate